

Allelic polymorphism in the T cell receptor and its impact on immune responses

Stephanie Gras,¹ Zhenjun Chen,² John J. Miles,⁴ Yu Chih Liu,¹ Melissa J. Bell,⁴ Lucy C. Sullivan,² Lars Kjer-Nielsen,² Rebekah M. Brennan,^{4,5} Jacqueline M. Burrows,⁴ Michelle A. Neller,⁴ Rajiv Khanna,⁴ Anthony W. Purcell,³ Andrew G. Brooks,² James McCluskey,² Jamie Rossjohn,¹ and Scott R. Burrows⁴

¹The Protein Crystallography Unit, Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3800, Australia

²Department of Microbiology and Immunology and ³Department of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria 3010, Australia

⁴Cellular Immunology Laboratory, Queensland Institute of Medical Research and Australian Centre for Vaccine Development, Brisbane, Queensland 4029, Australia

⁵School of Medicine, University of Queensland, Brisbane, Queensland 4029, Australia

In comparison to human leukocyte antigen (HLA) polymorphism, the impact of allelic sequence variation within T cell receptor (TCR) loci is much less understood. Particular TCR loci have been associated with autoimmunity, but the molecular basis for this phenomenon is undefined. We examined the T cell response to an HLA-B*3501-restricted epitope (HPVGEADYFEY) from Epstein-Barr virus (EBV), which is frequently dominated by a *TRBV9*01+* public TCR (TK3). However, the common allelic variant *TRBV9*02*, which differs by a single amino acid near the CDR2 β loop (Gln55→His55), was never used in this response. The structure of the TK3 TCR, its allelic variant, and a nonnaturally occurring mutant (Gln55→Ala55) in complex with HLA-B*3501^{HPVGEADYFEY} revealed that the Gln55→His55 polymorphism affected the charge complementarity at the TCR-peptide-MHC interface, resulting in reduced functional recognition of the cognate and naturally occurring variants of this EBV peptide. Thus, polymorphism in the TCR loci may contribute toward variability in immune responses and the outcome of infection.

CORRESPONDENCE

Scott R. Burrows:
Scott.Burrows@qimr.edu.au
OR
Jamie Rossjohn:
jamie.rossjohn@
med.monash.edu.au

Abbreviations used: BSA, buried surface area; CDR, complementarity-determining region; pMHC, peptide-MHC; SNP, single nucleotide polymorphism; SPR, surface plasmon resonance; vdW, van der Waals.

MHC molecules play a critical role in protective immunity by presenting antigenic peptide fragments for T cell recognition (Davis and Bjorkman, 1988). MHC polymorphism enhances immune defense across the population by ensuring wide variation in the T cell response to infecting pathogens through presentation of a broad array of target epitopes (Lawlor et al., 1990; Germain and Margulies, 1993). There are ~4,000 different variants of HLA (Robinson et al., 2003), with polymorphism generally concentrated in the antigen-binding cleft, controlling the size and diversity of the peptide repertoire presented by each HLA molecule. Although HLA molecules can differ from each other by >30 amino acids, differences of only a few amino acids (micropolymorphism) can have a major impact on immune responses (Archbold et al., 2009). Namely, HLA micropolymorphism

can influence the repertoire of peptides presented on the surface of APCs (Macdonald et al., 2003; Burrows et al., 2007), the conformation of HLA-bound peptide (Hülsmeier et al., 2004; Tynan et al., 2005c), the dependence on chaperones for antigen loading (Zernich et al., 2004), $\alpha\beta$ TCR recognition (Tynan et al., 2005a,b, 2007), and susceptibility to infectious disease (Limou et al., 2009).

To engage the vast repertoire of MHC-bound antigenic peptides, TCRs are diversified through the random rearrangement of V and J genes at the TCR α locus, and V, D, and J genes at the TCR β locus of developing thymic T cells. Further potential diversity is created through untemplated addition or deletion

S. Gras and Z. Chen contributed equally to this paper.

© 2010 Gras et al. This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see <http://www.rupress.org/terms>). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at <http://creativecommons.org/licenses/by-nc-sa/3.0/>).

of a variable number of nucleotides at the V-(D)-J junctional sites, called N regions. The residual repertoire of unique TCRs after thymic selection is between 10 and 100 million in humans (Arstila et al., 1999). Despite this vast potential repertoire, immune responses often show strong unexplained biases in TCR selection, resulting in immunodominance of certain “public” TCRs that are widely used in individuals with shared MHC types (Acha-Orbea et al., 1988; Arguet et al., 1994; Burrows et al., 1995; Turner et al., 2006; Gras et al., 2008). The first and second complementarity-determining regions (CDRs) of the TCR are germline encoded within the *TRAV* and *TRBV* gene segments, whereas the CDR3 regions are derived from the V-(D)-J and N regions. From the growing number of unique TCR–peptide–MHC (pMHC)–I structures determined, it is apparent that a rough docking mode is preserved in which the V α domain is positioned over the MHC-I α 2 helix and the N-terminal end of the peptide, whereas the V β domain is more often positioned over the MHC-I α 1 helix and the C-terminal end of the peptide, although the precise interatomic interactions vary considerably between TCR–pMHC complexes (Rudolph et al., 2006; Godfrey et al., 2008).

As with the MHC genes, allelic sequence variation is also a feature of the TCR loci; however, the full extent of TCR polymorphism and its functional significance in influencing protective immunity is unknown. Nevertheless, several single nucleotide polymorphism (SNP) studies have revealed considerable polymorphism within the *TRAV* and *TRBV* gene segments (Subrahmanyam et al., 2001; Mackelprang et al., 2006). In one study, the TCR loci from 40 individuals across four ethnic groups were fully sequenced, and >550 SNPs were found, with many being situated in coding/regulatory regions of functional TCR genes and several causing null and nonfunctional mutations. On average, the coding region of each TCR variable gene contained two SNPs, with many more found in the 5', 3', and intronic sequences of these segments. Furthermore, a total of 51 SNPs in the *TRA* locus and 72 SNPs in the *TRB* locus resulted in amino acid changes (Subrahmanyam et al., 2001; Mackelprang et al., 2006), although the structural and functional consequences of this sequence variation have not been investigated. Importantly, particular TCR loci have been associated with increased susceptibility to common immune diseases such as multiple sclerosis (Seboun et al., 1989; Hibberd et al., 1992; Hockertz et al., 1998), asthma (Moffatt et al., 1994, 1997; Cho et al., 2001), and narcolepsy (Hallmayer et al., 2009).

In this study, we have investigated the functional and structural impact of natural micropolymorphism within genes encoding a public TCR that recognizes an 11–amino acid epitope, ⁴⁰⁷HPVGEADYFEY⁴¹⁷ (referred to as HPVGE), derived from the EBNA-1 protein of EBV. This epitope is highly immunogenic in EBV-exposed healthy individuals expressing HLA-B*3501 (Blake et al., 1997; Lee et al., 2004; Tellam et al., 2004; Miles et al., 2006). Although EBV is a genetically stable DNA virus, sequence variation within the HPVGE epitope has been previously described (Snudden

et al., 1995; Wang et al., 2002; Zhang et al., 2004; Dolan et al., 2006). Unrelated EBV⁺, HLA-B*3501⁺ individuals frequently generate CTLs against the HPVGE epitope that express immunodominant public TCR α and β chains characterized by *TRAV*20, *TRAJ*58, *TRBV*9, and *TRBJ*2-2 usage (Miles et al., 2006). We now show that allelic variation within this *TRBV*9 gene, which led to a Gln (*TRBV*9*01) to His (*TRBV*9*02) substitution at position 55 (ImMunoGeneTics unique numbering; Lefranc, 2003), resulted in a reduction in TCR binding affinity and diminished functional recognition of the cognate viral epitope as well as the naturally occurring variants of this epitope. These factors dictate the preferential selection of the *TRBV*9*01 TCR β chain gene and the exclusion of *TRBV*9*02 in this antiviral immune response. Our data therefore illustrate both the sensitivity and significance of allelic polymorphism within the TCR loci in protective immunity.

RESULTS

Allelic variation in the *TRBV*9 gene

The HLA-B*3501–restricted CTL response to the HPVGEADYFEY epitope from EBV is characterized by type III–biased TCR usage (Miles et al., 2006; Turner et al., 2006), with biases in the *TRAV* and *TRBV* genes as well as conserved length and sequence motifs in the CDR3 loops. Specifically, in multiple clones from unrelated individuals, this biased response was defined by closely related TCRs, which comprised *TRAV*20/*TRAJ*58 combined with *TRBV*9/*TRBJ*2-2 (Miles et al., 2006). Notably, the CDR3 α and CDR3 β loops were largely germline encoded, although the CDR3 α loops displayed a strongly biased selection of the random N-nucleotide–encoded Leu, whereas the CDR3 β loops were characterized by a 3–amino acid “ARS/ART/VRT/APT” motif (Miles et al., 2006). Sequence data for three HPVGE-specific CTL clones, isolated from three unrelated HLA-B*3501⁺ individuals, are shown in Fig. 1 a. These strong gene biases and selection of recurrent motifs suggested that they play a crucial role in determining the specificity toward the HLA-B*3501^{HPVGE} complex.

Polymorphism within the *TRBV*9 gene is common across various ethnic groups, with the *TRBV*9*01 allele occurring more frequently than the *TRBV*9*02 allele (*TRBV*9*01: 82, 79, and 97%; and *TRBV*9*02: 18, 21, and 3% in Caucasians, African Americans, and Chinese, respectively; Brzezinski et al., 2005). A single amino acid difference distinguishes these two alleles, with *TRBV*9*01 encoding a Gln and *TRBV*9*02 encoding a His at position 55, which is a framework residue lying directly adjacent to the CDR2 loop of the β chain. Accordingly, we investigated the possibility that this TCR micropolymorphism could influence recognition of HLA-B*3501^{HPVGE}.

PBMCs were collected from 27 healthy, HLA-B35⁺, EBV-exposed individuals, and genomic *TRBV* sequencing revealed that 21 donors were homozygous for the *TRBV*9*01 allele, 6 donors were heterozygous for *TRBV*9*01 and *TRBV*9*02, and 0 donors were homozygous for the *TRBV*9*02 allele. To determine if both of these alleles could be used in




Figure 1. *TRBV9*01* is required for optimal recognition by a public TCR that dominates the response to the HPV viral epitope. (a) Highly conserved V-(D)-J junctional region sequences of TCR α and β chains from CTL clones that recognize HLA-B*3501^{HPVG}, isolated from three unrelated individuals. The nucleotide sequences are presented, and the one-letter code designating the translated amino acid is shown above the first nucleotide in each codon. Colored areas designate nucleotides of germline origin. (b) HLA-B*3501^{HPVG} multimer staining, and CD3 and CD8 cell-surface expression for JurkatCD8 cells transduced with the TK3^{WT}, TK3^{Gln55His} (two clones), or TK3^{Gln55Ala} TCR. Cells were stained with OKT3 (anti-CD3), anti-CD8a, or an HLA-B*3501^{HPVG} multimer at 4°C. Data for the untransfected parental line was left out of the histogram for simplicity. (c) The TCR-transduced JurkatCD8 cells were also stained at 37°C for 4 h with the HLA-B*3501^{HPVG} pentamer using a range of multimer concentrations (final concentration indicated on the x axis). Mean fluorescence intensity (MFI) of HLA-B*3501^{HPVG} pentamer staining is shown on the y axis. (d) Activation of the TCR-transduced JurkatCD8 cells with various concentrations of the HLA-B*3501^{HPVG} pentamer. CD69 up-regulation was used as a marker for cell activation. The binding of HLA-B*3501^{HPVG} pentamer was

performed at 37°C for 4 h. The cells were then washed and costained with APC-labeled anti-CD69 antibody for 30 min on ice. The experiments were conducted at least twice with similar results.

the response to the HPV epitope, an HLA-B*3501^{HPVG} multimer was used to sort T cells specific for the HPV epitope from five of the heterozygous donors who were confirmed to be HLA-B*3501⁺. cDNA from the expressed *TRBV9* gene products was cloned into *Escherichia coli*, and sequence analysis of at least 31 clones from each donor revealed that all were from the *TRBV9*01* allele, indicating that *TRBV9*02* was not used in the response to this EBV epitope (Table I). To confirm that these five heterozygous donors carried T cells expressing both *TRBV9*01* and *TRBV9*02* in their peripheral repertoire, the same cDNA sequencing procedure was used on unsorted PBMCs. Although T cells expressing *TRBV9*01* were more common in the peripheral repertoire than those expressing *TRBV9*02*, these data confirmed that *TRBV9*02*-expressing T cells were available in all five donors for potential use in antiviral T cell immunity (Table I).

Differential functional recognition

Next, we aimed to establish why the *TRBV9*01* allele was repeatedly selected in the response to HLA-B*3501^{HPVG}, whereas the *TRBV9*02* allele was not. Further TCR sequence analysis for the TK3 CTL clone (Fig. 1 a) confirmed that its β chain was encoded by the *TRBV9*01* allele, and it was therefore studied further as a prototype of this response.

The TCR-negative human T cell line Jurkat, which had been engineered to stably express CD8 (Beddoe et al., 2009), was transduced with retroviral expression constructs encoding (a) the TK3 TCR cDNA (JurkatCD8-TK3^{WT}), (b) the TK3 TCR with the naturally occurring Gln→His β -chain substitution corresponding to position 55 of *TRBV9* (JurkatCD8-TK3^{Gln55His}), or (c) a corresponding alanine mutant (JurkatCD8-TK3^{Gln55Ala}). After cloning, these CD8⁺ Jurkat T cells expressing the wild-type and mutant TK3 TCRs were closely matched for levels of both CD3 and CD8 (Fig. 1 b). An HLA-B*3501^{HPVG} multimer was used to assess antigen recognition by the TK3 TCR and its variants. The multimer incubation was performed at 4°C, and strong staining was observed for all cell lines (Fig. 1 b), confirming equivalent levels of TCR expression by the different transduced JurkatCD8 cell lines. However, when the multimer staining was repeated using a 37°C incubation instead of 4°C and a wide range of multimer concentrations, minor differences in staining intensity were observed between the cell lines, with two clones transduced with the TK3^{Gln55His} TCR staining with the lowest intensity (Fig. 1 c). This temperature sensitivity in multimer association suggested that the TK3^{Gln55His} TCR may bind with a lower avidity to the MHC-viral peptide complex in comparison to the TK3^{WT} TCR.

Table I. Expression of *TRBV9* alleles in T cells from HLA-B*3501⁺, EBV-sero⁺, *TRBV9*01-TRBV9*02* heterozygous individuals

| Donor | HLA-B*3501 ^{HPVG} multimer-sorted cells | | Unsorted PBMCs | |
|----------|---|-----------------|-----------------|-----------------|
| | <i>TRBV9*01</i> | <i>TRBV9*02</i> | <i>TRBV9*01</i> | <i>TRBV9*02</i> |
| Donor 7 | 31/31 | 0/31 | 16/26 | 10/26 |
| Donor 18 | 31/31 | 0/31 | 24/27 | 3/27 |
| Donor 23 | 31/31 | 0/31 | 20/29 | 9/29 |
| Donor 26 | 32/32 | 0/32 | 25/31 | 6/31 |
| Donor 27 | 36/36 | 0/36 | 19/29 | 10/29 |

Antigen-specific activation of the Jurkat transformants was then assayed by measuring up-regulation of cell-surface CD69 after incubation with varying concentrations of the HLA-B*3501^{HPVG} multimer. Although the JurkatCD8-TK3^{WT} and JurkatCD8-TK3^{Gln55Ala} cell lines were activated by the multimer, the JurkatCD8-TK3^{Gln55His} cells failed to show significant CD69 up-regulation after exposure to the pMHC complex (Fig. 1 d).

The JurkatCD8-TK3^{WT}, JurkatCD8-TK3^{Gln55His}, and JurkatCD8-TK3^{Gln55Ala} cell lines were compared in dose-response CD69 up-regulation experiments using synthetic HPVGEADYFEY peptide presented on the HLA-deficient C1R cell line that had been transfected to express HLA-B*3501. In contrast to data shown in Fig. 1 d for the HLA-B*3501^{HPVG} multimer, no significant differences in CD69 up-regulation were observed between the different cell lines after peptide stimulation (not depicted). We reasoned that the high levels of CD8 expression on the JurkatCD8 cells could mask TCR-pMHC affinity differences, and therefore the SKW3 thymoma cell line, which is TCR α and β deficient and lacks high levels of CD8 $\alpha\beta$ expression (Hundhausen et al., 1992), was also transduced to express either the TK3^{WT}, TK3^{Gln55His}, or TK3^{Gln55Ala} TCRs. When these cell lines were tested in CD69 up-regulation experiments using various concentrations of the HPVGEADYFEY peptide presented on C1R-HLA-B*3501 APCs, the SKW3-TK3^{Gln55His} cell line was found to require much higher peptide concentrations for equivalent CD69 up-regulation in comparison to the SKW3-TK3^{WT} and SKW3-TK3^{Gln55Ala} cell lines (Fig. 2 a). Collectively, these results establish that the TK3^{WT} TCR can recognize the HLA-B*3501^{HPVG} complex more efficiently than the allelic variant TK3^{Gln55His}.

HPVG sequence variants

Given the sensitivity of the TK3 TCR to micropolymorphism within the *TRBV9* gene, we next evaluated the impact of naturally occurring mutations in the HPVG epitope on recognition by the TK3^{WT}, TK3^{Gln55His}, and TK3^{Gln55Ala} TCRs. The dominant EBV strains infecting Caucasians encode the HPVGEADYFEY sequence, as demonstrated by a recent study that found that 42 out of 43 Australian Caucasians carried strains encoding this epitope (Bell et al., 2008). In contrast, the dominant strain in Chinese individuals includes

a conserved amino-acid substitution at position 5 (HPVG-DADYFEY; Wang et al., 2002; Zhang et al., 2004), and this variant was also found in six out of six viral strains from Papua New Guinea (unpublished data). Furthermore, the Ag876 strain of EBV, which represents the prototype type-2 EBV strain, encodes another variant of this epitope, HPVAEADYFEY (Dolan et al., 2006). A third variant, HPVGQADYFEY, has also been described in type-1 EBV isolates (Snudden et al., 1995; Bell et al., 2008).

The SKW3-TK3^{WT} cell line recognized the HPVGEADYFEY and HPVAEADYFEY peptides very efficiently, whereas suboptimal recognition was observed for the HPVGQADYFEY variant. The HPVG-DADYFEY variant failed to stimulate significant CD69 up-regulation at any peptide concentration (Fig. 2 b). As mentioned in the previous section, the SKW3-TK3^{Gln55His} cells were weakly responsive to the HPVGEADYFEY peptide, and the amino-acid substitutions at positions 4 or 5 resulted in further loss of stimulatory capacity (Fig. 2 c). The SKW3-TK3^{Gln55Ala} cell line showed similar specificity for the peptide variants as the SKW3-TK3^{WT} cell line (Fig. 2 d).

The TK3 CTL clone was raised from a healthy HLA-B*3501⁺, EBV-sero⁺ Caucasian individual (Miles et al., 2006). This primary CTL clone was next used in peptide dose-response cytotoxicity assays, using HLA-B*3501⁺ PHA blasts as target cells, to examine whether it could recognize the peptide variants. Although the HPVAEADYFEY peptide was recognized very well by the TK3 CTLs, the two mutations at position 5 in the EBV epitope led to a significant reduction in CTL lysis at limiting peptide concentrations (Fig. 2 e).

These data demonstrate that the public TCR expressed by the TK3 CTL clone was finely tuned for specific recognition of the HPVGEADYFEY epitope, although it is equally effective at recognizing the HPVAEADYFEY sequence encoded by type-2 strains of EBV. Furthermore, the data establish that selection of the *TRBV9*01* allele over the *TRBV9*02* allele for this public EBV-specific TCR ensures efficient recognition of the stimulating viral epitope and a greater capacity to tolerate mutations in the viral epitope.

Affinity measurements

To better understand the basis for the differential recognition of HLA-B*3501^{HPVG} and the HPVG variants by the TK3^{WT}, TK3^{Gln55His}, and TK3^{Gln55Ala} TCRs, surface plasmon resonance (SPR) studies were undertaken. The TK3^{WT} TCR and its two variants were expressed, refolded, and purified, and the yields of refolded protein were equivalent for each TCR. Further, the TK3^{WT}, TK3^{Gln55His}, and TK3^{Gln55Ala} TCRs appeared structurally intact in that they reacted with a conformationally specific anti-TCR mAb. By SPR analysis, the affinity (K_d) of the TK3^{WT} TCR for HLA-B*3501^{HPVG} was determined to be 2.2 μ M, whereas the affinity of the TK3^{Gln55His} and TK3^{Gln55Ala} TCRs for HLA-B*3501^{HPVG} was 34.7 and 5.8 μ M, respectively (Table II and Fig. 3). Interestingly, the TK3^{WT} TCR-HLA-B*3501^{HPVG} interaction had a ninefold slower off rate (0.085 ± 0.003 s⁻¹) when compared




Figure 2. T cell recognition of naturally occurring variants of the HPVGEADYFEY epitope.

(a) Activation of SKW3-TK3^{WT}, SKW3-TK3^{Gln55His}, and SKW3-TK3^{Gln55Ala} cell lines with various concentrations of the HPVGEADYFEY peptide, presented on C1R-HLA-B*3501 APCs. (b-d) Activation of SKW3-TK3^{WT} (b), SKW3-TK3^{Gln55His} (c), and SKW3-TK3^{Gln55Ala} (d) cell lines with various concentrations of the four variants of the HPVGEADYFEY sequence, presented on C1R-HLA-B*3501 APCs. Mean fluorescence intensity (MFI) of CD69 was determined and plotted against the concentration of peptide as indicated. (e) The primary TK3 CTL clone was tested for recognition of peptides corresponding to the HPVGEADYFEY epitope or three variant sequences in dose-response cytotoxicity assays using HLA-B*3501+ PHA blasts as target cells. The experiments were conducted at least twice with similar results.

with that of the TK3^{Gln55His} TCR-HLA-B*3501^{HPVG} interaction ($0.787 \pm 0.137 \text{ s}^{-1}$; Table II and Fig. 3).

We next used SPR to investigate the impact of the sequence variation within the HPVG epitope on recognition by the TK3, TK3^{Gln55His}, and TK3^{Gln55Ala} TCRs. Although the TK3^{WT} TCR bound the HLA-B*3501^{HPV<u>A</u>EADYFEY} variant with an affinity ($4.8 \mu\text{M}$) comparable to the cognate HLA-B*3501^{HPVGEADYFEY} epitope, its interaction with the HLA-B*3501^{HPVG<u>Q</u>ADYFEY} and HLA-B*3501^{HPVG<u>D</u>ADYFEY} variants was diminished (52 and $189 \mu\text{M}$, respectively; Table II and Fig. S1). Although the TK3^{Gln55Ala} TCR recognized the three peptide variants with comparable affinity to that of the TK3^{WT} TCR, the TK3^{Gln55His} TCR recognized the three peptide variants with much lower affinity ($75 \mu\text{M}$ for the HPV<u>A</u>EADYFEY variant, and $>200 \mu\text{M}$ for the HPVG<u>D</u>ADYFEY and HPVG<u>Q</u>ADYFEY variants; Table II and Fig. S1).

Thus, consistent with the earlier functional data, the TK3^{WT} TCR interacted with the HLA-B*3501-restricted HPVG epitope and its variants with a higher affinity when compared with the TK3^{Gln55His} TCR. This difference in affinity was primarily related to a much slower off rate for the wild-type TCR.

Overview of TK3 TCR-HLA-B*3501^{HPVG} structure

Given the different affinities of the TK3 and TK3^{Gln55His} TCRs toward the HLA-B*3501^{HPVG} complex, we hypothesized that these two TCRs would interact differently with the HLA-B*3501^{HPVG} complex. To investigate this hypothesis

and the structural basis for the observations described in the previous section, we purified the TK3 TCR-HLA-B*3501^{HPVG} complex, and solved the structure at 2-\AA resolution to an R_{fac} and R_{free} of 22.5 and 28.6% , respectively (Table S1). The initial experimental phases clearly showed unbiased electron density for the HPVG peptide (unpublished data), and moreover, the electron density at the TK3 TCR-HLA-B*3501^{HPVG} interface was unambiguous. The TK3 TCR docked at $\sim 66^\circ$ across the long axis of the HLA-B*3501^{HPVG} complex (Fig. 4, a and d) and thus falls within the range of roughly conserved docking orientations previously observed in TCR-pMHC complexes (Rudolph et al., 2006). Moreover, the TK3 TCR interacted with positions 65, 69, and 155 of HLA-B*3501, which is consistent with the observation that TCRs invariably interact with these three positions on pMHC-I (Tynan et al., 2005b; Rudolph et al., 2006). The TK3 TCR docked centrally on the HLA-B*3501^{HPVG} complex, in which the total buried surface area (BSA) at the interface was $\sim 2,050 \text{ \AA}^2$, with 172 van der Waals (vdw) interactions, 18 H bonds, and 3 salt bridges (Tables S2 and S3).

The V α and V β domains contributed roughly equally to the BSA at the TK3 TCR-HLA-B*3501^{HPVG} interface (55 and 45% , respectively; Fig. 4, a and d). All six CDR loops of the TK3 TCR contributed to interacting with HLA-B*3501^{HPVG}, albeit to varying degrees, and notably, a large number of framework-derived residues (12% BSA) participated in this interaction. Namely, residues within the framework region of the TK3 TCR contacted the peptide (see following section), and Arg66 β contacted residues Thr69, Gln72, and Thr73 on the $\alpha 1$ helix of HLA-B*3501 (Fig. 5 a and Table S2). Notably, Arg66 β is unique to *TRBV9* in that it is not found in any other *TRBV* genes. The CDR1 α and CDR2 α loops of the TK3 TCR contributed 17 and 5% to the BSA, respectively, and

Table II. Affinity measurements of the TK3, TK3^{Gln55His}, and TK3^{Gln55Ala} TCRs with HLA-B*3501 in complex with the HPVG peptide and its variants

| Immobilized ligand | Analyte | K_d | K_{on} | K_{off} | K_d calc |
|-------------------------|-----------------------------|---------------|------------------|---------------|---------------|
| | | μM | $\times 10^4/Ms$ | $1/s$ | μM |
| TK3 ^{WT} | B*3501-HPVGEADYFEY | 2.2 ± 0.2 | 4.01 ± 0.22 | 0.085 ± 0.003 | 2.21 ± 0.25 |
| TK3 ^{Gln55Ala} | B*3501-HPVGEADYFEY | 5.76 ± 0.07 | 1.65 ± 0.39 | 0.115 ± 0.004 | 7.345 ± 1.505 |
| TK3 ^{Gln55His} | B*3501-HPVGEADYFEY | 34.66 ± 1.66 | 3.08 ± 0.25 | 0.787 ± 0.137 | 25.6 ± 1.42 |
| TK3 ^{WT} | B*3501-HPV <u>A</u> EADYFEY | 4.8 ± 0.53 | 8.33 ± 2.35 | 0.2 ± 0.001 | 3.195 ± 0.115 |
| TK3 ^{Gln55Ala} | B*3501-HPV <u>A</u> EADYFEY | 12 ± 0.2 | ND | ND | ND |
| TK3 ^{Gln55His} | B*3501-HPV <u>A</u> EADYFEY | 74.5 ± 1.4 | ND | ND | ND |
| TK3 ^{WT} | B*3501-HPVGD <u>A</u> YGFY | 189 ± 6 | ND | ND | ND |
| TK3 ^{Gln55Ala} | B*3501-HPVGD <u>A</u> YGFY | 179 ± 6 | ND | ND | ND |
| TK3 ^{Gln55His} | B*3501-HPVGD <u>A</u> YGFY | >200 | ND | ND | ND |
| TK3 ^{WT} | B*3501-HPVGD <u>Q</u> AYGFY | 52.03 ± 12.83 | 0.151 ± 0.042 | 0.076 ± 0.002 | 54.75 ± 14.45 |
| TK3 ^{Gln55Ala} | B*3501-HPVGD <u>Q</u> AYGFY | 99.6 ± 1.4 | 0.08 ± 0.001 | 0.131 ± 0.002 | 163.5 ± 5.5 |
| TK3 ^{Gln55His} | B*3501-HPVGD <u>Q</u> AYGFY | >200 | ND | ND | ND |

Underlining indicates the variant amino acid.

the CDR1 β and CDR2 β loops contributed 1 and 12% to the BSA, respectively. The CDR3 loops collectively played the most prominent role, with the CDR3 α and CDR3 β loops contributing 32 and 19% of the BSA at the interface, respectively, thereby providing clues toward the restricted length and repeated CDR3 usage.

The CDR2 α loop was located peripheral to the α 2 helix, and consequently its interactions were limited to the bulky aromatic ring of Tyr57 α packing against the side chain of Arg151 (unpublished data). The CDR1 α loop sat above and predominantly interacted with the α 2 helix, in which Arg31 α interdigitized between Gln107 α and Leu109 α of the CDR3 α to plug a cavity between the HPVG peptide and the TCR α chain, and H bond to Gln155 (Fig. 5 b). The unusual interplay

between the CDR1 α and CDR3 α loops underpinned the restricted length of the CDR3 α loop and provided a basis for understanding the repeated usage of the N region-encoded Leu109 α residue. Moreover, Leu109 α formed several specificity-governing interactions with Gln155, the main chain of Tyr159 and Leu163. The small side chain of N region-encoded Gly110 α assisted in enabling the J α -encoded Ser112 α to form several vdw interactions with the main chain of Gln65, Ile66, and Thr69 and a water-mediated H bond with Asn70 (Fig. 5 c). The CDR1 β loop did not appreciably contact the MHC-I, whereas the CDR2 β loop interacted with the α 1 helix of HLA-B*3501: Glu61 β and Tyr57 β from the CDR2 β loop contacted Gln72 and Glu76, respectively (Table S2). The ¹⁰⁸ARS¹¹⁰ motif and Gly111 β of the CDR3 β loop contacted the tip of the α 2 helix (residues 149–151). Namely, the Arg109 β side chain interacted with Ala149, whereas its main chain interacted with Ala150. Ser110 β H bonded the main chain of Ala149 and contacted Arg151, the latter of which also contacted Gly111 β , and collectively,




Figure 3. SPR response sensograms for the TK3^{WT}, TK3^{Gln55Ala}, and TK3^{Gln55His} TCRs. (a–c) A range of concentrations of the re-folded HLA-B*3501^{HPVG} complex was used for SPR response analysis with the TK3^{WT} (a), TK3^{Gln55Ala} (b), and TK3^{Gln55His} (c) TCRs. (d) Binding curves for the three TCRs are shown, using graded concentrations of HLA-B*3501^{HPVG} (only showing from 50 to 0 μM). The experiments have been conducted in triplicate and the error bars are shown for each data point (means \pm SD).




Figure 4. Overview and footprint of the TK3^{WT}, TK3^{Gln55His}, and TK3^{Gln55Ala} TCRs in complex with HLA-B*3501^{HPVG}. (a–c) Ribbon representation of the TK3^{WT} (a), TK3^{Gln55His} (b), and TK3^{Gln55Ala} (c) TCRs in complex with HLA-B*3501^{HPVG}. The TCR α chain is in pale pink; the TCR β chain is in pale blue, green, or gray in TK3^{WT}, TK3^{Gln55His}, or TK3^{Gln55Ala}, respectively; HLA-B*3501 is in gray; and the HPV peptide is represented as a black stick. (d–f) The footprints of the TK3^{WT} (d), TK3^{Gln55His} (e), and TK3^{Gln55Ala} (f) TCRs on the HLA-B*3501^{HPVG} complex. Residues contacted by the CDR loops are colored in purple (CDR1 α), green (CDR2 α), yellow (CDR3 α), blue (CDR1 β), red (CDR2 β), or orange (CDR3 β) in all complexes. The interaction with the framework of the TCR β chain is colored in pale blue. The black spheres in d, e, and f represent the orientation of the $V\alpha$ and $V\beta$ chains for each TCR on the HLA-B*3501^{HPVG} complex, calculated by center of mass.

these interactions underpinned the biased selection of the “ARS” motif (Fig. 5 d).

Having determined the structure of HLA-B*3501^{HPVG} in the nonliganded state (Miles et al., 2006), we were able to observe the conformational changes that took place in HLA-B*3501 upon complexation with the TK3 TCR (conformational changes within the peptide are discussed in the following section). Although the overall conformation of HLA-B*3501 remained relatively rigid upon ligation (root mean square deviation = 0.4 Å), several HLA-B*3501 residues changed conformation to avoid clashes with or to form specificity-governing contacts with the TK3 TCR. For example, the side chain of Arg151 flipped conformation to fit between the aromatic ring of Tyr57 α from the CDR2 α loop and Gln155 of HLA-B*3501 (Fig. S2 a). The latter residue also changed conformation as a result of Arg31 α from the CDR1 α loop, which inserted its guanidinium head group between the α 2 helix of HLA-B*3501 and the HPV peptide. Within the α 1 helix there were five MHC residues (Asp61, Arg62, Gln65, Gln72, and Gln76) that changed conformation upon TK3 TCR ligation (Fig. S2 a). For example, the Arg62 was pushed outside the peptide-binding groove via the CDR3 α loop, which caused Arg62 to break its H bond with Gln65, which then transmitted to Gln65 forming a new interaction with Asp61. Accordingly, the principle role of the CDR3 loops in interacting with HLA-B*3501 was consistent with the biased CDR3 usage exhibited in this response.

Peptide-mediated contacts

In the nonliganded state, the central region (residues 5–8) of the HPV peptide was highly mobile within the antigen-binding cleft of HLA-B*3501 (Miles et al., 2006). Upon TK3

TCR ligation, this region of the peptide was stabilized, whereby the TK3 TCR contacted the peptide substantially and contributed 42% BSA at the pMHC interface, a value that is at the higher end when compared with the TCR–pMHC database (Rudolph et al., 2006). Collectively, five of the CDR loops interacted with the HPV peptide, contacting residues P3-Val to P8-Tyr and P10-Glu, forming a total of 81 vdw contacts, 13 H bonds, and 2 salt bridges (Table S3). P3-Val to P7-Asp were contacted by the CDR1 α and the CDR3 α loops, in which the role of the CDR1 α loop was restricted to Arg31 α interacting with P4-Gly and P6-Ala. The CDR3 α loop made extensive contact with the peptide (Fig. 5 e), with five residues of the HPV peptide (P3-Val to P7-Asp) contacted by five CDR3 α residues (Leu109 α and from Thr111 α to Ser114 α ; Fig. 5 e). Because of its small side chains, the ¹¹¹TSGS¹¹⁴ motif (found exclusively in *TRAJ58*) was in very close proximity to the HPV peptide, making a large number of contacts from P4-Gly to P7-Asp. The C-terminal region of the peptide, from P7-Asp to P10-Glu, was contacted by the three CDR β loops (Fig. 5 f) and also by three residues of the β -chain framework (Tyr40 β , Gln55 β , and Arg66 β ; Fig. 6 a). The P8-Tyr side chain was enveloped by the three CDR β loops, in which the CDR1 β was located above the P8-Tyr, forming contacts with Asp29 β , Leu30 β , and Ser31 β . This latter observation further explains *TRBV9* usage, as none of the other 54 *TRBV* genes have the “DLS” motif in CDR1 β . In addition, the P8-Tyr side chain was flanked by the Tyr57 β of the CDR2 β loop and the CDR3 β (Ser107 β , Ala108 β , and Arg109 β) in a manner that permitted the Arg109 β side chain to wrap around the aromatic ring of P8-Tyr (Fig. 5 f). The CDR2 β loop sat above the P10-Glu, which formed an H bond with Tyr57 β as well as a salt bridge with the framework residue, Arg66 β (Fig. 5 f and Fig. 6 a). The P7-Asp formed vdw interactions




Figure 5. TK3^{WT} contacts with HLA-B*3501 and with the HPV peptide.

(a–d) Contacts between the HLA-B*3501 molecule and the TK3^{WT} FWβ (a), CDR1α and CDR3α (b), CDR3α (c), and CDR3β (d) are shown, with the HLA-B*3501 and selected side chains depicted in white. The CDR loops and selected side chains of the TCR are colored as in Fig. 4 for all of the panels, and the peptide is represented as a pink stick. The blue and red dashed lines represent the vdw and polar interactions, respectively, and the red sphere represents a water molecule.

(e and f) Interactions between the HPV peptide and the TCR. (e) The interaction between the CDR1α and CDR3α with residues P4–P7 of the HPV peptide. (f) The interaction between the three CDRβ loops with the HPV peptide.

with the CDR1β and CDR3β loops, an H bond with Ser107β, and vdw contacts and an H bond with the framework residue Tyr40β (Fig. 5 f). Additionally, P7-Asp^{Oδ2–Oδ1} H bonded to the polymorphic residue Gln55β^{Nε2} (Fig. 6 a and Table S3).

As mentioned in the previous paragraph, an earlier study found that the central region (residues 5–8) of the HPV peptide was highly mobile within the antigen-binding cleft of HLA-B*3501 in the nonliganded state and, therefore, the peptide conformation could not be modeled in its entirety (Miles et al., 2006). However, the bulged peptide was more stable when bound to HLA-B*3508, which differs from HLA-B*3501 at a single amino acid (position 156; Miles et al., 2006). We were therefore able to compare the conformation of the central bulged region of the peptide in the HLA-B*3508^{HPVG} unliganded structure and in the TK3 TCR–HLA-B*3501^{HPVG} complex. This comparison suggested that the conformation of the peptide bulge was altered in the TCR-ligated complex, allowing the TCR to maximize MHC-I contacts (Fig. S2 b). The TCR regions responsible for these changes in peptide conformation are the CDR3α loop and the framework residues Arg66β and Gln55β. Accordingly, the TK3 TCR substantially contacted the HPV peptide and included an interaction with the polymorphic Gln55β residue.

The structural impact of micropolymorphism within the *TRBV9* gene

To investigate the structural impact of the sequence micropolymorphism between the *TRBV9*01* and *TRBV9*02* alleles, we next determined the structure of the TK3^{Gln55His} TCR–HLA-B*3501^{HPVG} complex to 2.1-Å resolution with an R_{fac} and R_{free} of 22.8 and 27.6%, respectively (Fig. 4, b and e). Additionally, we solved the structure of the TK3^{Gln55Ala} TCR–HLA-B*3501^{HPVG} complex to 2.7-Å resolution to establish why the Gln55Ala mutation did not affect the affin-

ity of the interaction when compared with that of the cognate interaction (Fig. 4, c and f; and Tables S1–S3). Both ternary complexes crystallized in the same space group and unit cell dimensions as that of the cognate complex, and thus, any structural differences observed could be attributable to the mutation at *TRBV9* position 55 in the TK3 TCR.

The TK3^{Gln55His} and TK3^{Gln55Ala} TCRs engaged HLA-B*3501^{HPVG} similarly to that of the TK3 TCR–HLA-B*3501^{HPVG} complex (overall root mean square deviation = 0.62 and 0.92 Å, respectively; Fig. 4, b and c), burying a similar surface area (2,025 and 1,920 Å² for TK3^{Gln55His} and TK3^{Gln55Ala}, respectively). However, the Gln55His mutation caused a decrease in the number of contacts (155 vdw contacts, 15 H bonds, and 2 salt bridges) with HLA-B*3501^{HPVG} when compared with the TK3 TCR–HLA-B*3501^{HPVG} complex (172 vdw contacts, 18 H bonds, and 3 salt bridges), and the number of contacts with the TK3^{Gln55Ala} TCR was decreased further (129 vdw, 13 H bonds, and 1 salt bridge; Tables S2 and S3). Compared with the interaction involving Gln55β in the cognate complex (Fig. 6 a), His55β H bonded to P7-Asp of the HPV peptide in a similar manner (Fig. 6 b). In the TK3^{Gln55Ala} TCR–HLA-B*3501^{HPVG} complex, the interaction between position 55 and the HPV epitope was lost (Fig. 6 c). Thus, the loss of contacts with HLA-B*3501^{HPVG} at position 55 with P7-Asp was not the sole discriminator for the weaker affinity of the TK3^{Gln55His} TCR when compared with the TK3 TCR, as the TK3^{Gln55Ala} TCR displayed a loss of contacts without decreasing the affinity for HLA-B*3501^{HPVG}.

Within the TK3 TCR, the neutral Gln55β residue sat within a basic pocket, flanked by Arg115α and Arg66β, and additionally surrounded by the main chain N atoms of R115α, S114α, and G113α. Upon ligation with HLA-B*3501^{HPVG}, the negative charge of the P7-Asp residue was effectively neutralized by H bonding to Gln55β and salt bridging to Arg66β. However, in the TK3^{Gln55His} TCR, position 55




Figure 6. Interactions with the polymorphic TCR residue. (a–c) Interaction between the TK3^{WT} (a), TK3^{Gln55His} (b), and TK3^{Gln55Ala} (c) TCRs with the peptide, localized at the polymorphic site of the β chain. The different chains are colored as in Fig. 4, the residues involved in the interaction are represented as sticks, and all of the panels show the same orientation of the different structures. (b) Loss of a direct H bond between the Arg66 β and D7, and also between the Arg115 α and the Ser112 α in the TK3^{Gln55His} structure when com-

pared with the TK3^{WT} (a). The loss of contacts is greater in the TK3^{Gln55Ala} structure (c) when compared with the TK3^{WT} complex (a). The blue and red dashed lines represent the vdw and polar interactions, respectively, and the red sphere represents a water molecule.

was replaced by the positively charged His residue, thereby creating a more electropositively charged pocket within the TK3 TCR. To accommodate this additional positive charge, the conformations of these neighboring Arg residues were subtly altered, resulting in the loss of a direct salt bridge between P7–Asp and Arg66 β , the loss of a direct H bond between Arg115 α and Ser112 α -O, and a reduction in the vdw contacts with HLA-B*3501 (Fig. 6 b and Fig. S2 c). Consequently, the TK3^{Gln55His} TCR less readily accommodates the negative charge of the P7–Asp, which accounts for the 10 times faster dissociation of the TK3^{Gln55His}–HLA B*3501^{HPVG} complex when compared with both the TK3^{WT} and TK3^{Gln55Ala} TCRs in complex with the same pHLA (Table II). Accordingly, altered charge complementarity at the interface between the TK3 TCR and HLA-B*3501^{HPVG} underpinned the weaker interaction and faster dissociation with the TK3^{Gln55His} TCR, and the preferential selection of *TRBV9*01* over *TRBV9*02* in this response.

DISCUSSION

Given the central role that T cells play in immune responses and immune-related disorders, polymorphism in the TCR genes has long been suspected as a potential candidate for disease susceptibility, and recent studies identifying extensive allelic sequence variation in the TCR V genes support this contention (Subrahmanyam et al., 2001; Mackelprang et al., 2006). Indeed, genomic polymorphisms of TCR genes have been found in association with common immune diseases such as multiple sclerosis (Seboun et al., 1989; Hibberd et al., 1992; Hockertz et al., 1998), asthma (Moffatt et al., 1994, 1997; Cho et al., 2001), and narcolepsy (Hallmayer et al., 2009); however, the mechanisms controlling these effects are not understood. Although these associations imply that micropoly-morphism within the TCR genes can influence T cell recognition and/or repertoire selection, our present study is the first to directly characterize the structural and functional impact of allelic sequence variation in the TCR loci. Our demonstration that a single amino-acid difference within a *TRBV* gene can reduce TCR binding affinity for a viral peptide–MHC complex and preclude its dominant selection in an antiviral T cell response sheds light on how allelic polymorphism in the TCR loci affects the adaptive immune response. Furthermore,

the molecular basis for these functional differences was revealed by structural studies showing that micropoly-morphism within the *TRBV9* gene affects stabilizing interactions between the TCR β chain and the antigenic peptide.

By examining TCR usage in the response to the HPVG viral epitope in donors heterozygous for two common alleles of the *TRBV9* gene segment, we showed that *TRBV9*01*-expressing T cells, but not *TRBV9*02*-expressing T cells, were selected in this highly biased T cell response. The basis for this observation became clear from experiments that showed reduced affinity and functional recognition of the HLA-B*3501^{HPVG} complex when the *TRBV9*02* TCR was used in place of the wild-type *TRBV9*01* TCR. In contrast, an earlier study demonstrated that the *TRBV9*02* allele was used by an HLA-A2–restricted human immunodeficiency virus pol-specific CTL clone, and that introducing a Gln (as in *TRBV9*01*) in place of the His residue at *TRBV* position 55 resulted in loss of recognition of the viral peptide (Vessey et al., 1996). These contrasting observations suggest a functional basis for the retention of these closely related *TRBV9* alleles in diverse human populations. Thus, selection pressure from various pathogens may maintain both *TRBV9*01* and *TRBV9*02* in the population because each imparts distinct T cell specificity characteristics that may favor recognition of different peptide–MHC complexes. Further, a previous report demonstrated that allelic polymorphism in the CDR1 domain of a mouse V β 10 gene segment affected recognition of a foreign peptide derived from an HLA molecule (Bour et al., 1999), supporting the conclusion that TCR gene polymorphism can influence specificity and TCR selection in CD8⁺ T cell responses.

Our previous TCR repertoire analysis of the response to the HPVG epitope showed that *TRBV9*⁺ T cells dominated in four out of five HLA-B*3501⁺ donors, but a fifth donor used both *TRBV9*⁺ and *TRBV28*⁺ T cells in roughly equal numbers (Miles et al., 2006), establishing that *TRBV9* is not an absolute requirement for recognition of this HLA-B*3501^{HPVG} complex. Although 0 out of 27 HLA-B35⁺, EBV-exposed individuals recruited for the present study was homozygous for the *TRBV9*02* allele, it is likely that such donors would respond to the HPVG epitope with TCRs encoded by V β genes other than *TRBV9*. Thus,

retention of the *TRBV9*02* allele in the population may increase the overall TCR repertoire diversity against this epitope, thereby protecting the population against viral epitope variants that escape recognition by the dominant public TCR. The HPVGDADYFEY epitope variant, for example, which is found in EBV strains infecting Chinese individuals, was recognized suboptimally by the public *TRBV9*01*⁺ TK3 TCR and particularly poorly by the TK3^{Gln55His} TCR, and therefore, alternative TCRs are likely to be recruited in the response to this peptide.

A study of polymorphism within the human *TRBV* gene segments showed that nonsynonymous variants are evenly distributed between the framework and CDR regions (50 in framework regions and 8 in CDR regions), and it was suggested that the SNPs mapped to the CDR regions may alter the avidity or specificity of the TCR (Subrahmanyam et al., 2001). Our data demonstrate that coding polymorphisms within framework residues are also functionally relevant, directly affecting TCR affinity toward HLA-B*3501^{HPVG}, thereby raising the possibility that coding polymorphisms anywhere along the *TRBV* gene could potentially influence immune function.

Recently, structural studies have suggested that the germline-encoded regions of a TCR dictate MHC bias (Feng et al., 2007; Dai et al., 2008; Scott-Browne et al., 2009). However, we show in this study that the germline-encoded polymorphic residue within *TRBV9* exclusively contacted the viral epitope, and this interaction effectively determined the functional outcome of this MHC-restricted response.

This study has highlighted the structural and functional relevance of nonsynonymous TCR V gene polymorphism, suggesting that it may have evolved to further diversify the immune repertoire. Given the structural and functional impact of the *TRBV* gene polymorphism documented in this paper, it will be important to examine the complementary role of TCR polymorphism and MHC associations in autoimmune disease involving well-defined self-antigens. Our data provide insights into the mechanisms controlling disease associations with allelic sequence variation in the TCR loci, and suggest its potentially important role in shaping the antiviral T cell repertoire, thereby contributing toward inter-individual variability in T cell responses and the outcome of infection.

MATERIALS AND METHODS

TCR sequencing. The CTL clones TK3, MW1, and CS1 have been characterized previously, and TCR α and β chain sequences were determined as previously described (Miles et al., 2006). For *TRBV9* genotyping, genomic DNA samples were obtained from PBMCs from 27 healthy, HLA-B*35⁺ EBV-exposed Caucasian individuals. The polymorphic region of the *TRBV9* gene segment was amplified by PCR using the primers 5'-TTCAG-GCTCCTCTGCTGTGT-3' and 5'-GTGGGGCAGGAATGTTATTG-3'. The PCR products were purified using the MinElute PCR Purification Kit (QIAGEN) and directly sequenced in both directions using the BigDye Terminator reaction kit (Applied Biosystems).

To examine *TRBV9*01* versus *TRBV9*02* expression in the T cell repertoire, total RNA was extracted using TRIzol reagent from PBMCs or HLA-B*3501^{HPVG}-specific T cells isolated by FACS after staining with a pMHC pentamer (ProImmune). A one-step SuperScript II PCR reaction kit

(Invitrogen) was used with a *TRBV9* family-specific primer (5'-AGTCA-CACAAACCCCAAAGC-3') and a constant region primer (5'-TTCT-GATGGCTCAAACAC-3'). The PCR products were purified and cloned into the pGEM-T vector system (Promega) and sequenced using the BigDye Terminator reaction kit. Human protocols were approved by the Queensland Institute of Medical Research Human Research Ethics Committee.

TCR cloning, protein expression, and purification. cDNA was reverse transcribed from TK3 T cell RNA using SuperScript II. PCR products encoding the TK3 TCR α and β chains were cloned into pGEM-T Easy before cotransferring into the pMIG vector (Holst et al., 2006). The primers were as follows (italicized nucleotides represent restriction sites and lower-cased nucleotides represent TCR gene sequences): P1, 5'-CGGAATTCGCTAGCACCATggagaaaattgttgagtgt-3'; P2, 5'-GGGCCCTGGGTTCTCTTCGACGTCGCCGGCCTGCTTAAGCAGCGAGAAATGGTG-GCCCGGATCCgctggaccacagccgagcgt-3'; P3, 5'-GGATCCGGCGC-CACCAATTCTCGTGCTTAAGCAGGCCGGCGACGTCGAAGA-GAACCCAGGGCCatgggctcaggtcctctcgc-3'; and P4, 5'-CCGCTCGA-GCTGCAGctagcctctggaatcctctt-3'.

The variant TCRs TK3 β ^{Gln55His} and TK3 β ^{Gln55Ala} were generated from the parental pGEM-TK3 α ^{WT}-2A-TK3 β ^{WT} plasmid DNA through site-directed mutagenesis. The corresponding inserts were transferred to the pMIG vector and the resulting constructs were denoted as pMIG-TK3^{WT} (TK3 α ^{WT}-2A-TK3 β ^{WT}), pMIG-TK3^{Gln55His} (TK3 α ^{WT}-2A-TK3 β ^{Gln55His}), and pMIG-TK3^{Gln55Ala} (TK3 α ^{WT}-2A-TK3 β ^{Gln55Ala}). The mutagenesis primers were as follows (underlined nucleotides represent mutation codons): Gln55Ala P5, 5'-CTCCAGTTCCTCATTGCGTATTATAATGGAGAAG-3'; P6, 5'-CTTCTCCATTATAATACGCAATGAGGAAGACTGGAG-3'; Gln55His P7, 5'-CTCCAGTTCCTCATTGCACTATTATAATGGAGAAG-3'; and P8, 5'-CTTCTCCATTATAATAGTGAATGAGGAAGACTGGAG-3'.

The TK3^{WT}, TK3^{Gln55His}, and TK3^{Gln55Ala} TCRs were expressed, refolded, and purified using an engineered disulfide linkage in the constant domains between the *TRAC* and *TRBC*. Both the α and β chains of the TK3^{WT} TCR and the mutant versions were expressed separately as inclusion bodies in the BL21 *E. coli* strain. Inclusion bodies were resuspended in 8 M urea, 20 mM Tris-HCl, pH 8, 0.5 mM Na-EDTA, and 1 mM dithiothreitol. The TCRs were refolded by flash dilution in a solution containing 3 M urea, 100 mM Tris, pH 8, 2 mM Na-EDTA, 400 mM L-arginine-HCl, 0.5 mM of oxidized glutathione, and 5 mM of reduced glutathione. The refolding solution was dialyzed to eliminate the urea. The resulting protein solution was purified by gel filtration and HiTrap-Q anion exchange chromatography.

Soluble class I heterodimers containing the HPVG peptide (or variant peptides) were prepared as described previously (Macdonald et al., 2002). In brief, a truncated form (amino-acid residues 1–276) of the HLA-B*3501 heavy chain and full-length β 2-microglobulin (β 2m) were expressed in *E. coli* as inclusion bodies. Each HLA-B*3501-peptide complex was refolded by diluting the heavy chain and β 2m inclusion body preparations into refolding buffer containing a molar excess of peptide ligand. The refolded complexes were concentrated and purified by anion exchange chromatography. The complexes were further purified by gel filtration and HiTrap-Q anion exchange chromatography.

Retroviral transduction into JurkatCD8 and SKW3 cells. JurkatCD8 cells were generated previously, and they lack a TCR β chain (TCR α ⁺ β ⁻; Beddoe et al., 2009). SKW3 cells are TCR α ⁻ β ⁻ (double deficient), and they were purchased from the German Collection of Microorganisms and Cell Cultures.

JurkatCD8-TK3^{WT}, JurkatCD8-TK3^{Gln55Ala}, and JurkatCD8-TK3^{Gln55His} cell lines were created via retroviral transduction as described previously (Holst et al., 2006; Beddoe et al., 2009). In brief, the plasmids pMIG-TK3^{WT}, pMIG-TK3^{Gln55Ala}, or pMIG-TK3^{Gln55His} (4 μ g) were individually combined with the packaging vectors pPAM-E (4 μ g) and pVSV-g (2 μ g) and cotransfected into 10⁶ 293T cells in a 10-cm dish with FuGENE 6 (Roche) as previously described (Holst et al., 2006). The transiently transfected 293T cells were further cultured for 5 d. During this time, the retrovirus-containing supernatant was collected twice daily and used to transduce JurkatCD8 cells along with

6 µg/ml polybrene. At the end of the transduction, JurkatCD8 cells were analyzed for expression of the TK3 αβ TCR with HLA-B*3501^{HPVG} pentamer staining by FACS. JurkatCD8-TK3αβ-positive cells were enriched by FACS and were subsequently cloned by single-cell sorting using flow cytometry. SKW3-TK3^{WT}, SKW3-TK3^{Gln55Ala}, and SKW3-TK3^{Gln55His} cell lines were generated similarly. In these transduced cell lines, GFP expression levels correlated very well with the surface expression levels of CD3.

FACS. 2×10^5 JurkatCD8-TK3 or SKW3-TK3 cells were stained with OKT3 antibody (anti-CD3) on ice for 30 min or with peptide-loaded HLA class I multimers (HLA-B*3501^{HPVG} pentamer) on ice or at 37°C for 45 min. When antibody costaining was also performed, pentamer binding was performed first, followed by costaining antibodies. After washing twice with FACS buffer (PBS containing 2% fetal calf serum and 0.02% azide), the cells were run through a FACSCalibur or FACSaria with CellQuest software (all from BD) and analyzed with FlowJo software (Tree Star, Inc.). For cell sorting, cells were similarly stained and all steps were performed in a biohazardous hood and with filter-sterile reagents.

T cell activation assay. 10^5 JurkatCD8-TK3 cells were cultured with or without antigen stimulation for 2 or 4 h at 37°C. The antigen stimulation treatments involved peptide-loaded HLA class I multimer binding. The cells were pelleted and assayed for CD69 up-regulation by antibody staining and FACS. T cell activation was measured by the increase of the mean fluorescence of CD69 staining with gated JurkatCD8-TK3 cells. SKW3-TK3 cell activation assays were conducted similarly, with the exception of pulsing the APCs (C1R-B*3501) first with peptides at the concentration indicated in the figures for 1 h at 37°C before adding an equivalent number of SKW3-TK3 cells.

Cytotoxicity assays. The primary TK3 CTL clone was tested in duplicate for cytotoxicity in standard 5-h chromium release assays. In brief, CTLs were assayed against ⁵¹Cr-labeled autologous PHA blast targets (effector/target = 2:1) that were pretreated with various concentrations of synthetic peptide or left untreated. Peptides were synthesized by Mimotopes Ltd. Toxicity testing of all peptides was performed before use by adding peptide to ⁵¹Cr-labeled PHA blasts in the absence of CTL effectors. A β scintillation counter (Topcount Microplate; PerkinElmer) was used to measure ⁵¹Cr levels in assay supernatant samples. The mean spontaneous lysis for target cells in the culture medium was always <20%, and the variation from the mean specific lysis was <10%.

SPR measurement and analysis. All SPR experiments were conducted at 25°C on the BIAcore 3000 instrument (GE Healthcare) with HBS buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, and 0.005% surfactant P20). The HBS buffer was supplemented with 1% bovine serum albumin to prevent nonspecific binding. The human TCR-specific mAb 12H8 (Borg et al., 2005) was coupled to research-grade CM5 chips with standard amine coupling. For each experiment, the TCRs (TK3, TK3^{Gln55His}, or TK3^{Gln55Ala}) were passed over the flow cell until ~200–400 response units were captured by the antibody. One flow cell was left empty to be used as a control cell for each experiment. HLA-B*3501, either in complex with the wild-type or variant peptides, were injected over all four flow cells at a rate of 20 µl/min with a concentration range of 0.78–200 µM. The final response was calculated by subtraction of the response of the antibody alone from that of the antibody–TK3^{WT}, –TK3^{Gln55His}, or –TK3^{Gln55Ala} complexes. The antibody surface was regenerated between each analyte injection with Actisep (Sterogene). All experiments were conducted at least in duplicate.

BIAevaluation (version 3.1) was used for data analysis, and the 1:1 Langmuir binding model was modified to include an additional parameter for the drifting baseline for the TCR capture by the 12H8 antibody to calculate the kinetic constants.

Crystallization. Crystals of the TK3^{WT}–HLA-B*3501^{HPVG} complex were grown by the hanging-drop, vapor-diffusion method at 20°C with a protein/reservoir drop ratio of 1:1, at a concentration of 6 mg/ml in 10 mM Tris, pH 8, and 150 mM NaCl. Large rhombus-shaped crystals grew using 15%

PEG 3350, 0.2 M Li₂SO₄, and 0.1 M Na-citrate, pH 5.6. The crystals of TK3^{Gln55His} and TK3^{Gln55Ala} in complex with HLA-B*3501^{HPVG} were obtained in the same conditions.

Data collection and structure determination. The TCR–pMHC crystals were soaked in a cryoprotectant solution containing mother liquor solution with a PEG concentration increased to 30% (wt/vol), and were flash frozen in liquid nitrogen. The data were collected on the 3BM1 beamline at the Australian Synchrotron, Clayton using a charge-coupled device detector at 100 K (Quantum 210; Area Detector Systems Corporation). Data were processed using XDS software and scaled using XSCALE software (Kabsch, 1993).

The TK3–HLA-B*3501^{HPVG} crystal (and the other complexes) belonged to the space group *P1* (Table S1), with unit cell dimensions consistent with one complex in the asymmetric unit. The structure was determined by molecular replacement using the PHASER program (Read, 2001) with the CF34 TCR as the search model for the TCR (PDB accession no. 3FFC; Gras et al., 2009) and the HLA-B*3501^{HPVG} complex for the MHC model without the peptide (PDB accession no. 2FYI; Miles et al., 2006). Manual model building was conducted using COOT software (Emsley and Cowtan, 2004), followed by maximum-likelihood refinement with the REFMAC 5 program (CCP4 suite; Collaborative Computational Project, Number 4, 1994; Murshudov et al., 1997). Translation, liberation, and screw-rotation displacement refinement was also used during the refinement process to model anisotropic displacements of defined domains. The TCR was numbered according to the ImmunoGeneTics unique numbering system (Lefranc, 2003), whereby the CDR1 loops start at residue 27, the CDR2 loops start at residue 56, and the CDR3 loops start at residue 105. The final model was validated using the PDB validation web site and the final refinement statistics are summarized in Table S1. All molecular graphics representations were created using PyMOL (DeLano, 2002).

PDB accession numbers. The coordinates of the TK3^{WT}–HLA-B*3501^{HPVG}, TK3^{Gln55His}–HLA-B*3501^{HPVG}, and TK3^{Gln55Ala}–HLA-B*3501^{HPVG} complexes have been deposited under PDB accession nos. 3MV7, 3MV8, and 3MV9, respectively.

Online supplemental material. Table S1 summarizes data collection and refinement statistics for the structural studies. Table S2 lists the TCR–MHC contacts in the three TCR–pMHC complexes. Table S3 lists the TCR–peptide contacts in the three TCR–pMHC complexes. Fig. S1 shows SPR data for the TK3^{WT}, TK3^{Gln55His}, and TK3^{Gln55Ala} TCRs with HLA-B*3501 bound to HPVG and its natural variants. Fig. S2 shows conformational changes in the pMHC upon ligation with TK3^{WT}, and structural differences between the TK3^{WT}–HLA-B*3501^{HPVG} and TK3^{Gln55His}–HLA-B*3501^{HPVG} complexes. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20100603/DC1>.

This work was supported by the Australian Research Council (ARC; Federation Fellowship to J. Rossjohn) and the National Health and Medical Research Council (NHMRC) of Australia (Career Development Award to L.C. Sullivan; Senior Research Fellowships to S.R. Burrows, A.W. Purcell, and R. Khanna; C.J. Martin Overseas Biomedical Fellowship to J.J. Miles; and Dora Lush Scholarship to R.M. Brennan), and by grants from the NHMRC and ARC.

The authors have no conflicting financial interests.

Submitted: 25 March 2010

Accepted: 4 May 2010

REFERENCES

- Acha-Orbea, H., D.J. Mitchell, L. Timmermann, D.C. Wraith, G.S. Tausch, M.K. Waldor, S.S. Zamvil, H.O. McDevitt, and L. Steinman. 1988. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. *Cell*. 54:263–273. doi:10.1016/0092-8674(88)90558-2
- Archbold, J.K., W.A. Macdonald, S. Gras, L.K. Ely, J.J. Miles, M.J. Bell, R.M. Brennan, T. Beddoe, M.C. Wilce, C.S. Clements, et al. 2009.

- Natural micropolymorphism in human leukocyte antigens provides a basis for genetic control of antigen recognition. *J. Exp. Med.* 206:209–219. doi:10.1084/jem.20082136
- Argaet, V.P., C.W. Schmidt, S.R. Burrows, S.L. Silins, M.G. Kurilla, D.L. Doolan, A. Suhrbier, D.J. Moss, E. Kieff, T.B. Sculley, and I.S. Misko. 1994. Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus. *J. Exp. Med.* 180:2335–2340. doi:10.1084/jem.180.6.2335
- Arstila, T.P., A. Casrouge, V. Baron, J. Even, J. Kanellopoulos, and P. Kourilsky. 1999. A direct estimate of the human alphabeta T cell receptor diversity. *Science*. 286:958–961. doi:10.1126/science.286.5441.958
- Beddoe, T., Z. Chen, C.S. Clements, L.K. Ely, S.R. Bushell, J.P. Vivian, L. Kjer-Nielsen, S.S. Pang, M.A. Dunstone, Y.C. Liu, et al. 2009. Antigen ligation triggers a conformational change within the constant domain of the alphabeta T cell receptor. *Immunity*. 30:777–788. doi:10.1016/j.immuni.2009.03.018
- Bell, M.J., R. Brennan, J.J. Miles, D.J. Moss, J.M. Burrows, and S.R. Burrows. 2008. Widespread sequence variation in Epstein-Barr virus nuclear antigen 1 influences the antiviral T cell response. *J. Infect. Dis.* 197:1594–1597. doi:10.1086/587848
- Blake, N., S. Lee, I. Redchenko, W. Thomas, N. Steven, A. Leese, P. Steigerwald-Mullen, M.G. Kurilla, L. Frappier, and A. Rickinson. 1997. Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. *Immunity*. 7:791–802. doi:10.1016/S1074-7613(00)80397-0
- Borg, N.A., L.K. Ely, T. Beddoe, W.A. Macdonald, H.H. Reid, C.S. Clements, A.W. Purcell, L. Kjer-Nielsen, J.J. Miles, S.R. Burrows, et al. 2005. The CDR3 regions of an immunodominant T cell receptor dictate the 'energetic landscape' of peptide-MHC recognition. *Nat. Immunol.* 6:171–180. doi:10.1038/ni1155
- Bour, H., O. Michielin, P. Bouso, J.C. Cerottini, and H.R. MacDonald. 1999. Dramatic influence of V beta gene polymorphism on an antigen-specific CD8+ T cell response in vivo. *J. Immunol.* 162:4647–4656.
- Brzezinski, J.L., R. Deka, A.G. Menon, D.N. Glass, and E. Choi. 2005. Variability in TRBV haplotype frequency and composition in Caucasian, African American, Western African and Chinese populations. *Int. J. Immunogenet.* 32:413–420. doi:10.1111/j.1744-313X.2005.00550.x
- Burrows, S.R., S.L. Silins, D.J. Moss, R. Khanna, I.S. Misko, and V.P. Argaet. 1995. T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen. *J. Exp. Med.* 182:1703–1715. doi:10.1084/jem.182.6.1703
- Burrows, J.M., K.K. Wynn, F.E. Tynan, J. Archbold, J.J. Miles, M.J. Bell, R.M. Brennan, S. Walker, J. McCluskey, J. Rossjohn, et al. 2007. The impact of HLA-B micropolymorphism outside primary peptide anchor pockets on the CTL response to CMV. *Eur. J. Immunol.* 37:946–953. doi:10.1002/eji.200636588
- Cho, S.H., J.W. Son, Y.Y. Koh, K.U. Min, Y.Y. Kim, and Y.K. Kim. 2001. Linkage between bronchial responsiveness to methacholine and gene markers of IL-4 cytokine gene cluster and T-cell receptor alpha/delta gene complex in Korean nuclear families. *Clin. Exp. Allergy*. 31:103–109.
- Collaborative Computational Project, Number 4. 1994. The CCP4 suite: programs for protein crystallography. *Acta Crystallogr. D Biol. Crystallogr.* 50:760–763.
- Dai, S., E.S. Huseby, K. Rubtsova, J. Scott-Browne, F. Crawford, W.A. Macdonald, P. Marrack, and J.W. Kappler. 2008. Crossreactive T cells spotlight the germline rules for alphabeta T cell-receptor interactions with MHC molecules. *Immunity*. 28:324–334. doi:10.1016/j.immuni.2008.01.008
- Davis, M.M., and P.J. Bjorkman. 1988. T-cell antigen receptor genes and T-cell recognition. *Nature*. 334:395–402. doi:10.1038/334395a0
- DeLano, W.L. 2002. PyMOL Molecular Viewer. <http://www.pymol.org/> (accessed July 15, 2004).
- Dolan, A., C. Addison, D. Gatherer, A.J. Davison, and D.J. McGeoch. 2006. The genome of Epstein-Barr virus type 2 strain AG876. *Virology*. 350:164–170. doi:10.1016/j.virol.2006.01.015
- Emsley, P., and K. Cowtan. 2004. Coot: model-building tools for molecular graphics. *Acta Crystallogr. D Biol. Crystallogr.* 60:2126–2132. doi:10.1107/S0907444904019158
- Feng, D., C.J. Bond, L.K. Ely, J. Maynard, and K.C. Garcia. 2007. Structural evidence for a germline-encoded T cell receptor-major histocompatibility complex interaction 'codon'. *Nat. Immunol.* 8:975–983. doi:10.1038/ni1502
- Germain, R.N., and D.H. Margulies. 1993. The biochemistry and cell biology of antigen processing and presentation. *Annu. Rev. Immunol.* 11:403–450. doi:10.1146/annurev.iv.11.040193.002155
- Godfrey, D.I., J. Rossjohn, and J. McCluskey. 2008. The fidelity, occasional promiscuity, and versatility of T cell receptor recognition. *Immunity*. 28:304–314. doi:10.1016/j.immuni.2008.02.004
- Gras, S., L. Kjer-Nielsen, S.R. Burrows, J. McCluskey, and J. Rossjohn. 2008. T-cell receptor bias and immunity. *Curr. Opin. Immunol.* 20:119–125. doi:10.1016/j.coi.2007.12.001
- Gras, S., S.R. Burrows, L. Kjer-Nielsen, C.S. Clements, Y.C. Liu, L.C. Sullivan, M.J. Bell, A.G. Brooks, A.W. Purcell, J. McCluskey, and J. Rossjohn. 2009. The shaping of T cell receptor recognition by self-tolerance. *Immunity*. 30:193–203. doi:10.1016/j.immuni.2008.11.011
- Hallmayer, J., J. Faraco, L. Lin, S. Hesselson, J. Winkelmann, M. Kawashima, G. Mayer, G. Plazzi, S. Nevsimalova, P. Bourgin, et al. 2009. Narcolepsy is strongly associated with the T-cell receptor alpha locus. *Nat. Genet.* 41:708–711. doi:10.1038/ng.372
- Hibberd, M.L., B.A. Millward, F.S. Wong, and A.G. Demaine. 1992. T-cell receptor constant beta chain polymorphisms and susceptibility to type 1 diabetes. *Diabet. Med.* 9:929–933. doi:10.1111/j.1464-5491.1992.tb01733.x
- Hockertz, M.K., D.W. Paty, and S.S. Beall. 1998. Susceptibility to relapsing-progressive multiple sclerosis is associated with inheritance of genes linked to the variable region of the TcR beta locus: use of affected family-based controls. *Am. J. Hum. Genet.* 62:373–385. doi:10.1086/301700
- Holst, J., A.L. Szymczak-Workman, K.M. Vignali, A.R. Burton, C.J. Workman, and D.A. Vignali. 2006. Generation of T-cell receptor retrogenic mice. *Nat. Protoc.* 1:406–417. doi:10.1038/nprot.2006.61
- Hülsmeier, M., M.T. Fiorillo, F. Bettosini, R. Sorrentino, W. Saenger, A. Ziegler, and B. Uchanska-Ziegler. 2004. Dual, HLA-B27 subtype-dependent conformation of a self-peptide. *J. Exp. Med.* 199:271–281. doi:10.1084/jem.20031690
- Hundhausen, T., R. Laus, and W. Müller-Ruchholtz. 1992. New parental cell lines for generating human hybridomas. *J. Immunol. Methods*. 153:21–29. doi:10.1016/0022-1759(92)90301-9
- Kabsch, W. 1993. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. *J. Appl. Cryst.* 26:795–800. doi:10.1107/S0021889893005588
- Lawlor, D.A., J. Zemmour, P.D. Ennis, and P. Parham. 1990. Evolution of class-I MHC genes and proteins: from natural selection to thymic selection. *Annu. Rev. Immunol.* 8:23–63. doi:10.1146/annurev.iv.08.040190.000323
- Lee, S.P., J.M. Brooks, H. Al-Jarrah, W.A. Thomas, T.A. Haigh, G.S. Taylor, S. Humme, A. Schepers, W. Hammerschmidt, J.L. Yates, et al. 2004. CD8 T cell recognition of endogenously expressed Epstein-Barr virus nuclear antigen 1. *J. Exp. Med.* 199:1409–1420. doi:10.1084/jem.20040121
- Lefranc, M.P. 2003. IMGT, the international ImMunoGeneTics database. *Nucleic Acids Res.* 31:307–310. doi:10.1093/nar/gkg085
- Limou, S., S. Le Clerc, C. Coulonges, W. Carpentier, C. Dina, O. Delaneau, T. Labib, L. Taing, R. Sladek, C. Deveau, et al; ANRS Genomic Group. 2009. Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02). *J. Infect. Dis.* 199:419–426. doi:10.1086/596067
- Macdonald, W., D.S. Williams, C.S. Clements, J.J. Gorman, L. Kjer-Nielsen, A.G. Brooks, J. McCluskey, J. Rossjohn, and A.W. Purcell. 2002. Identification of a dominant self-ligand bound to three HLA B44 alleles and the preliminary crystallographic analysis of recombinant forms of each complex. *FEBS Lett.* 527:27–32. doi:10.1016/S0014-5793(02)03149-6
- Macdonald, W.A., A.W. Purcell, N.A. Mifusud, L.K. Ely, D.S. Williams, L. Chang, J.J. Gorman, C.S. Clements, L. Kjer-Nielsen, D.M. Koelle, et al. 2003. A naturally selected dimorphism within the HLA-B44 supertype alters class I structure, peptide repertoire, and T cell recognition. *J. Exp. Med.* 198:679–691. doi:10.1084/jem.20030066
- Mackelprang, R., R.J. Livingston, M.A. Eberle, C.S. Carlson, Q. Yi, J.M. Akey, and D.A. Nickerson. 2006. Sequence diversity, natural selection

- and linkage disequilibrium in the human T cell receptor alpha/delta locus. *Hum. Genet.* 119:255–266. doi:10.1007/s00439-005-0111-z
- Miles, J.J., N.A. Borg, R.M. Brennan, F.E. Tynan, L. Kjer-Nielsen, S.L. Silins, M.J. Bell, J.M. Burrows, J. McCluskey, J. Rossjohn, and S.R. Burrows. 2006. TCR alpha genes direct MHC restriction in the potent human T cell response to a class I-bound viral epitope. *J. Immunol.* 177:6804–6814.
- Moffatt, M.F., M.R. Hill, F. Cornélis, C. Schou, J.A. Faux, R.P. Young, A.L. James, G. Ryan, P. le Souef, A.W. Musk, et al. 1994. Genetic linkage of T-cell receptor alpha/delta complex to specific IgE responses. *Lancet.* 343:1597–1600. doi:10.1016/S0140-6736(94)93057-0
- Moffatt, M.F., C. Schou, J.A. Faux, and W.O. Cookson. 1997. Germline TCR- α restriction of immunoglobulin E responses to allergen. *Immunogenetics.* 46:226–230. doi:10.1007/s002510050266
- Murshudov, G.N., A.A. Vagin, and E.J. Dodson. 1997. Refinement of macromolecular structures by the maximum-likelihood method. *Acta Crystallogr. D Biol. Crystallogr.* 53:240–255. doi:10.1107/S0907444996012255
- Read, R.J. 2001. Pushing the boundaries of molecular replacement with maximum likelihood. *Acta Crystallogr. D Biol. Crystallogr.* 57:1373–1382. doi:10.1107/S0907444901012471
- Robinson, J., M.J. Waller, P. Parham, N. de Groot, R. Bontrop, L.J. Kennedy, P. Stoehr, and S.G. Marsh. 2003. IMGT/HLA and IMGT/MHC: sequence databases for the study of the major histocompatibility complex. *Nucleic Acids Res.* 31:311–314. doi:10.1093/nar/gkg070
- Rudolph, M.G., R.L. Stanfield, and I.A. Wilson. 2006. How TCRs bind MHCs, peptides, and coreceptors. *Annu. Rev. Immunol.* 24:419–466. doi:10.1146/annurev.immunol.23.021704.115658
- Scott-Browne, J.P., J. White, J.W. Kappler, L. Gapin, and P. Marrack. 2009. Germline-encoded amino acids in the alphabeta T-cell receptor control thymic selection. *Nature.* 458:1043–1046. doi:10.1038/nature07812
- Seboun, E., M.A. Robinson, T.H. Doolittle, T.A. Ciulla, T.J. Kindt, and S.L. Hauser. 1989. A susceptibility locus for multiple sclerosis is linked to the T cell receptor beta chain complex. *Cell.* 57:1095–1100. doi:10.1016/0092-8674(89)90046-9
- Snudden, D.K., P.R. Smith, D. Lai, M.H. Ng, and B.E. Griffin. 1995. Alterations in the structure of the EBV nuclear antigen, EBNA1, in epithelial cell tumours. *Oncogene.* 10:1545–1552.
- Subrahmanyam, L., M.A. Eberle, A.G. Clark, L. Kruglyak, and D.A. Nickerson. 2001. Sequence variation and linkage disequilibrium in the human T-cell receptor beta (TCRB) locus. *Am. J. Hum. Genet.* 69:381–395. doi:10.1086/321297
- Tellam, J., G. Connolly, K.J. Green, J.J. Miles, D.J. Moss, S.R. Burrows, and R. Khanna. 2004. Endogenous presentation of CD8⁺ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1. *J. Exp. Med.* 199:1421–1431. doi:10.1084/jem.20040191
- Turner, S.J., P.C. Doherty, J. McCluskey, and J. Rossjohn. 2006. Structural determinants of T-cell receptor bias in immunity. *Nat. Rev. Immunol.* 6:883–894. doi:10.1038/nri1977
- Tynan, F.E., N.A. Borg, J.J. Miles, T. Beddoe, D. El-Hassen, S.L. Silins, W.J. van Zuylen, A.W. Purcell, L. Kjer-Nielsen, J. McCluskey, et al. 2005a. High resolution structures of highly bulged viral epitopes bound to major histocompatibility complex class I. Implications for T-cell receptor engagement and T-cell immunodominance. *J. Biol. Chem.* 280:23900–23909. doi:10.1074/jbc.M503060200
- Tynan, F.E., S.R. Burrows, A.M. Buckle, C.S. Clements, N.A. Borg, J.J. Miles, T. Beddoe, J.C. Whisstock, M.C. Wilce, S.L. Silins, et al. 2005b. T cell receptor recognition of a ‘super-bulged’ major histocompatibility complex class I-bound peptide. *Nat. Immunol.* 6:1114–1122. doi:10.1038/ni1257
- Tynan, F.E., D. Elhassen, A.W. Purcell, J.M. Burrows, N.A. Borg, J.J. Miles, N.A. Williamson, K.J. Green, J. Tellam, L. Kjer-Nielsen, et al. 2005c. The immunogenicity of a viral cytotoxic T cell epitope is controlled by its MHC-bound conformation. *J. Exp. Med.* 202:1249–1260. doi:10.1084/jem.20050864
- Tynan, F.E., H.H. Reid, L. Kjer-Nielsen, J.J. Miles, M.C. Wilce, L. Kostenko, N.A. Borg, N.A. Williamson, T. Beddoe, A.W. Purcell, et al. 2007. A T cell receptor flattens a bulged antigenic peptide presented by a major histocompatibility complex class I molecule. *Nat. Immunol.* 8:268–276. doi:10.1038/ni1432
- Vessey, S.J., J.I. Bell, and B.K. Jakobsen. 1996. A functionally significant allelic polymorphism in a T cell receptor V beta gene segment. *Eur. J. Immunol.* 26:1660–1663. doi:10.1002/eji.1830260739
- Wang, W.Y., Y.C. Chien, J.S. Jan, C.M. Chueh, and J.C. Lin. 2002. Consistent sequence variation of Epstein-Barr virus nuclear antigen 1 in primary tumor and peripheral blood cells of patients with nasopharyngeal carcinoma. *Clin. Cancer Res.* 8:2586–2590.
- Zernich, D., A.W. Purcell, W.A. Macdonald, L. Kjer-Nielsen, L.K. Ely, N. Laham, T. Crockford, N.A. Mifsud, M. Bharadwaj, L. Chang, et al. 2004. Natural HLA class I polymorphism controls the pathway of antigen presentation and susceptibility to viral evasion. *J. Exp. Med.* 200:13–24. doi:10.1084/jem.20031680
- Zhang, X.S., H.H. Wang, L.F. Hu, A. Li, R.H. Zhang, H.Q. Mai, J.C. Xia, L.Z. Chen, and Y.X. Zeng. 2004. V-val subtype of Epstein-Barr virus nuclear antigen 1 preferentially exists in biopsies of nasopharyngeal carcinoma. *Cancer Lett.* 211:11–18. doi:10.1016/j.canlet.2004.01.035